Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

ACCELERON PHARMA INC.

(XLRN)
RiassuntoQuotazioniGraficiNotizieRatingSocietąFinanzaDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ACCELERON PHARMA INC.
2021GLOBAL MARKETS LIVE: Airbus, BP, Merck, Pfizer, Meta...
2021Todo fuego, todo llama
2021Tout feu, tout flamme
2021EN DIRECT DES MARCHES: L'Oréal, Nestlé, Airbus, Soitec, Valneva, Ubisoft, HelloFresh, Der..
2021Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
2021ACCELERON PHARMA INC.(NASDAQGM: XLRN) dropped from NASDAQ Biotechnology Index
2021ACCELERON PHARMA: Completion of Acquisition or Disposition of Assets - Form 8-K
2021ACCELERON PHARMA INC: Completion of Acquisition or Disposition of Assets, Notice of Delis..
2021MERCK: l'acquisition d'Acceleron est finalisée
2021Merck Completes Acceleron Pharma Acquisition
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
2021Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
2021ACCELERON PHARMA INC.(NASDAQGM: XLRN) dropped from NASDAQ Composite Index
2021ACCELERON PHARMA INC.(NASDAQGM: XLRN) dropped from S&P Global BMI Index
2021ACCELERON PHARMA INC.(NASDAQGM: XLRN) dropped from S&P TMI Index
2021ACCELERON PHARMA INC.(NASDAQGM: XLRN) dropped from S&P Biotechnology Select Industry Inde..
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc
2021Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro..
2021Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offe..
2021Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
2021MERCK: l'OPA sur Acceleron va être prolongée
2021Merck Extends Tender Offer for Acceleron Pharma
2021Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Ten..
2021Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K
2021ACCELERON: Q3 Earnings Snapshot
2021ACCELERON PHARMA INC Management's Discussion and Analysis of Financial Condition and R..
2021Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
2021Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
2021Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95
2021Acceleron Reports Third Quarter 2021 Financial Results
2021SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its ..
2021Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o..
2021MORNING BRIEFING - USA/Asien -2-
2021WOCHENEND-ÜBERBLICK Unternehmen/30. und 31. Oktober 2021
2021Andienungsfrist für Merck-Angebot an Acceleron-Aktionäre verlängert sich
2021Merck Extends FTC Review Period for Acceleron Buyout
2021Merck prevé hasta 7.000 millones de dólares en ventas del medicamento COVID-19 hasta fi..
2021Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
2021Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of ..
2021ACCELERON PHARMA INC: Results of Operations and Financial Condition (form 8-K)
2021Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
2021Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 3..
2021MERCK: Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
2021ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender ..
2021MERCK: Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
2021SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pha..
2021ACCELERON PHARMA: Holocene Advisors says Merck's offer undervalues Acceleron
2021ACCELERON PHARMA: Holocene Advisors says Merck's offer undervalues Acceleron
2021MERCK: Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share
2021MERCK: lancement d'une OPA sur Acceleron Pharma
2021PLANÈTE BOURSE: La revue de presse du mercredi 6 octobre 2021
2021PRESSESPIEGEL/Unternehmen
2021ANALYSE/Mercks neues Covid-19-Mittel ist Segen für den Markt
2021ACCELERON INVESTOR ALERT BY THE FORM: Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
2021SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Sharehol..
2021Autumn cold snap
2021ANALYST RECOMMENDATIONS: Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
2021MERCK: le rachat d'Acceleron Pharma est scellé
2021PLANÈTE BOURSE: La revue de presse du vendredi 1er octobre 2021
2021NORTH AMERICAN MORNING BRIEFING: Fears Heighten -2-
2021MERCK: to Buy Rare Disease Specialist Acceleron for $11.5 Billion
2021Merck to buy Acceleron for about $11.5 billion in rare disease drug push
2021Health Care Down, But Not By Much, As Deal Activity Cushions Losses - Health Care Round..
2021Avoro Capital Discloses its Views on Proposed Acquisition of Acceleron Pharma to Merck ..
2021Wall Street sluit kwartaal lager af
2021ACCELERON PHARMA: Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merc..
2021Health Care Stocks Closing Slightly Lower After Early Gains
2021ACCELERON MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the..
2021Health Care Stocks Unable to Sustain Early Rise
2021SHAREHOLDER ALERT: Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fa..
2021Markets take a breather after the purge
2021MERCK: to Buy Acceleron for $11.5 Billion, or $180 Per Share in Cash, to Expand Cardiovas..
2021Merck doet miljardenovername
2021ACCELERON PHARMA: Merck spends $11.5B for Acceleron, possible blockbuster drug
2021Le laboratoire Merck & Co rachète Acceleron pour 11,5 milliards
1  2  3  4  5  6  7  8  9Pross.